.png){kind=icon}
.png){kind=icon}
Return
Short-course blinatumomab as a bridge-to-transplantation improves the survival of Ph-negative MRD-positive B-ALL
.png){kind=icon}
PRE
AI
M
H
J
X
Y
Y
C
B
K
L
Y
X
DOI：10.1177/09636897261466817.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
<jats:p>
Post-transplant relapse remains the chief therapeutic challenge in Ph-negative B cell acute lymphoblastic leukemia (Ph
<jats:sup>-</jats:sup>
B-ALL). This retrospective study evaluated whether short-course blinatumomab for measurable resident disease (MRD) eradication could improve transplant outcomes. We compared 23 patients receiving pre-transplant short-course blinatumomab (2-week) for MRD eradication with 46 chemotherapy-only controls. All achieved MRD-negative before allogeneic peripheral blood stem cell transplantation (allo-PBSCT). Only two patients developed grade 2 cytokine release syndrome with blinatumomab. The neutrophil and platelet engraftment times were similar between the two groups. The blinatumomab cohort had a significantly lower 18-month cumulative incidence (CI) of relapse (
<jats:italic toggle="yes">p</jats:italic>
= 0.05) and chronic graft-versus-host disease (GVHD) (14.8%
<jats:italic toggle="yes">vs.</jats:italic>
41.8%;
<jats:italic toggle="yes">p</jats:italic>
= 0.05), with comparable non-relapse mortality (NRM) (
<jats:italic toggle="yes">p</jats:italic>
= 0.98) and 180-day grade II-IV acute GVHD rates (
<jats:italic toggle="yes">p</jats:italic>
= 0.93). Consequently, this cohort showed superior 18-month relapse-free survival (RFS) (90.9%
<jats:italic toggle="yes">vs.</jats:italic>
65.2%; HR 0.30, 95% CI 0.09-1.04;
<jats:italic toggle="yes">p</jats:italic>
= 0.04), improved 18-month overall survival (OS) (95.7%
<jats:italic toggle="yes">vs.</jats:italic>
81.9%; HR 0.20, 95% CI 0.03-1.71), and a trend toward better GVHD-free and relapse-free survival (GRFS) (74.71%
<jats:italic toggle="yes">vs.</jats:italic>
63.71%; HR 0.64, 95% CI 0.23-1.78). Multivariate analysis confirmed blinatumomab as an independent favorable factor for RFS. In conclusion, short-course blinatumomab as a bridge-to-transplantation could reduce the risk of relapse and improve survival for Ph
<jats:sup>-</jats:sup>
B-ALL patients undergoing allo-PBSCT.
</jats:p>
Journal
IF:
3.2
Papers:
3.7K
Citations:
6.8K
Organization
Cited Papers